

Regimen Reference Order – BRST – olaparib

ARIA: BRST – [olaparib (ADJ)]

Planned Course: Twice daily until disease progression or unacceptable toxicity up to 1 year
(1 cycle = 30 days)

Indication for Use: Breast Cancer, Adjuvant, BRCA mutation positive

Proceed with treatment if:

ANC equal to or greater than $1.2 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – BRST – olaparib

Drug	Dose	CCMB Administration Guideline
olaparib	300 mg	Orally twice daily with or without food Swallow whole (Self-administered at home)
olaparib (LYNPARZA®) available dosage strengths: 100 mg and 150 mg tablets Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

INSTRUCTIONS FOR PATIENT

- Instruct patient to continue taking anti-emetic(s) at home
- olaparib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on olaparib

ADDITIONAL INFORMATION

- olaparib can rarely cause pneumonitis
- Secondary malignancy (MDS/AML) has been reported with olaparib (rare). Monitor for prolonged cytopenia
- olaparib is teratogenic. Women of childbearing potential should use contraception while on olaparib
- olaparib will be dispensed by CCMB Pharmacy